Physician profile
Joseph Duffy
NPI 1386897544
$1,019.28
in general payments reported to CMS, 2019-2025
18 companies · $23.84 in 2025
The $23.84 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $145 · 2021: $76.16 · 2022: $370 · 2023: $314 · 2024: $90.14 · 2025: $23.84.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $428.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $428.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $254.79 | 2019-2024 | Fasenra, Breztri, Airsupra |
| Mylan Specialty L.P. | $98.04 | 2019-2023 | Yupelri |
| Genzyme Corporation | $86.24 | 2022-2023 | |
| Harmony Biosciences LLC | $73.03 | 2021-2024 | |
| Actelion Pharmaceuticals US, INC. | $65.86 | 2022-2023 | Opsumit, Uptravi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.92 | 2021-2023 | Spiriva Respimat, Ofev |
| Regeneron Healthcare Solutions, INC. | $54.76 | 2019-2022 | |
| Insmed, INC. | $52.16 | 2019-2024 | Arikayce |
| Jazz Pharmaceuticals INC. | $49.81 | 2022-2023 | |
| Genentech USA, INC. | $39.95 | 2019 | |
| Grifols USA, LLC | $37.47 | 2022-2025 | Prolastin-C Liquid |
| Amgen INC. | $32.71 | 2022-2023 | Tezspire |
| United Therapeutics Corporation | $26.70 | 2023 | Tyvaso |
| Covis Pharma Gmbh | $23.60 | 2022 | |
| Idorsia Pharmaceuticals US INC | $21.63 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $15.54 | 2023 | |
| Sunovion Pharmaceuticals INC. | $13.07 | 2019 | |
| Glaxosmithkline, LLC. | $12.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Duffy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.